BZE2204
Cell therapy
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT07174843 NCT07174843 · Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP), Systemic Lupus Erythematosus(SLE) Registry: NCT07174843 | 1 | The frequency and severity of adverse events(AE) and serious adverse events(SAE) (From leukapheresis to 6 months post CAR-T infusion); The frequency of dose-limiting toxicity(DLT) (Day0 to Day28) 2027-08 | In progress: results expected 1 Aug 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Systemic Lupus Erythematosus: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| BZE2204: this drug | Phase 1 | Cell therapy | CD19, CD22, and BCMA (tri-antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor subunit 1 (IFNAR1) | Partial signal | NCT04931563: Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo (Week 52): Anifrolumab 300mg 84/138 vs Placebo 46/138 NCT02446899: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 (Baseline; Week 52): Anifrolumab 300 mg 86/180 (47.8%) vs Placebo 57/182 (31.3%) | |
| Belimumab (GSK1550188) (Benlysta) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | Weak signal | NCT00410384: SRI response at Week 52: 43.2% with belimumab 10 mg/kg vs 33.5% with placebo (p=0.0167); 40.6% with belimumab 1 mg/kg vs 33.5% with placebo (p=0.0889). | |
| Hydroxychloroquine | Approved | Small molecule | Autophagy/lysosomal acidification | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Deucravacitinib (Sotyktu) | Phase 3 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Litifilimab | Phase 3 | Monoclonal antibody | BDCA2 (CLEC4C), BDCA2 / CD303 (blood dendritic cell antigen 2) | Reliable signal | NCT02847598: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 (Baseline to Week 24): Part A: BIIB059 50 mg -9 joints (Standard Deviation 5.7) | Part A: BIIB059 150 mg -13 joints | Part A: BIIB059 450 mg -14.5 joints (Standard Deviation 8.7) vs Part A: Placebo -12.7 joints (Standard Deviation 10.3) | |
| Obinutuzumab Beta (Bejescin) | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Upadacitinib (Rinvoq) | Phase 3 | Small molecule | JAK, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Voclosporin (Lupkynis) | Phase 3 | Small molecule | Calcineurin, Cyclophilin A (leading to calcineurin inhibition) | Reliable signal | No reviewed efficacy summary in this indication | |
| Afimetoran | Phase 2 | Small molecule | TLR7/8 | not yet graded | No reviewed efficacy summary in this indication | |
| BI 3000202 | Phase 2 | Small molecule | cGAS (cyclic GMP-AMP synthase) | not yet graded | No reviewed efficacy summary in this indication | |
| Blinatumomab | Phase 2 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Envudeucitinib | Phase 2 | Small molecule | TYK2 | Partial signal | NCT05966480: LUMUS trial (NCT05966480), primary endpoint BICLA response: envudeucitinib did not meet its primary endpoint in the overall trial population, but a prespecified IFNGS-high subgroup showed robust clinical responses on the same primary endpoint (BICLA). missed | |
| Frexalimab | Phase 2 | Monoclonal antibody | CD40 ligand (CD40L / CD154) | not yet graded | No reviewed efficacy summary in this indication | |
| FT819 | Phase 2 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ICG318 | Phase 2 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Inebilizumab | Phase 2 | Monoclonal antibody | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Nomelcitinib (D-2570) | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Obexelimab | Phase 2 | Monoclonal antibody | CD19 / FcγRIIb | Partial signal | NCT02725515: Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225 (Day 225): XmAb5871 21/50 vs Placebo 12/42 missed | |
| Sanritatug | Phase 2 | Monoclonal antibody | CD38 | Weak signal | No reviewed efficacy summary in this indication | |
| TQH3906 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| VENT-03 | Phase 2 | Small molecule | cGAS (cyclic GMP-AMP synthase) | not yet graded | No reviewed efficacy summary in this indication | |
| Zolacabtagene Autoleucel | Phase 2 | Cell therapy | — | not yet graded | No reviewed efficacy summary in this indication | |
| Aritinercept | Phase 1/2(overall) | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0120 | Phase 1/2 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Beijing Biotech Anti-CD19 CAR-T | Phase 1/2 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Budoprutug | Phase 1/2 | Monoclonal antibody | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| DS-7011a | Phase 1/2 | Monoclonal antibody | Toll-like receptor 7 (TLR7) (inhibitor) | Weak signal | NCT05638802: Treatment-emergent adverse events: 11/19 DS-7011a participants vs 4/6 placebo participants. | |
| Lisaftoclax | Phase 1/2 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| SCTC21C | Phase 1/2 | Biologic (subtype unspecified) | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-319 | Phase 1 | Antibody–drug conjugate | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-519 | Phase 1 | — | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ANX009 | Phase 1 | Antibody fragment | C1q | not yet graded | No reviewed efficacy summary in this indication | |
| AZD5492 | Phase 1 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| BCD-256 | Phase 1 | Monoclonal antibody | BDCA2 (CLEC4C) | not yet graded | No reviewed efficacy summary in this indication | |
| BCMA-CD19 Compound CAR (cCAR) T Cells | Phase 1 | Cell therapy | BCMA / CD19 | Weak signal | NCT05474885: All patients (12/13) who received an initial dose of 3x10^6 cCAR cells/kg were negative for all autoantibodies, including those derived from long-lived plasma cells, 3 months post-cCAR. Therapy was well tolerated with mild cytokine-release syndrome (no CRS above grade 1), and mean SLE Disease Activity Index 2000 (SLEDAI-2K) fell from 9.9 at baseline to 2.3 at 3 months. | |
| Cevostamab | Phase 1 | Multispecific antibody | FcRH5 (FcRL5) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Cizutamig | Phase 1 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| CLN-978 | Phase 1 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Divozilimab (Ivlizi) | Phase 1 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| F01 | Phase 1 | Cell therapy | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4527363 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK5926371 | Phase 1 | Biologic (subtype unspecified) | CD19 / CD20 (dual-antigen) with CD3 T-cell engagement | not yet graded | No reviewed efficacy summary in this indication | |
| HC022 | Phase 1 | — | — | Weak signal | No reviewed efficacy summary in this indication | |
| IC19 CAR-T | Phase 1 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| LBL-047 | Phase 1 | Protein / enzyme therapeutic | BDCA2 (CLEC4C) / TACI | not yet graded | No reviewed efficacy summary in this indication | |
| NIM-1324 | Phase 1(overall) | Small molecule | LANCL2 | not yet graded | No reviewed efficacy summary in this indication | |
| Odronextamab | Phase 1 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| PIT565 | Phase 1 | Multispecific antibody | CD19 x CD2 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| SAR448501 | Phase 1 | Multispecific antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Surovatamig | Phase 1 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| UTAA09 | Phase 1 | Cell therapy | CD19 | Weak signal | No reviewed efficacy summary in this indication | |
| UTAA91 | Phase 1 | Cell therapy | CD19 (B cells) and PD-1+ pathogenic T cells | not yet graded | No reviewed efficacy summary in this indication | |
| Vonsetamig | Phase 1 | — | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| ZM001 | Phase 1 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Zugocabtagene Geleucel | Phase 1 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| FT522 | —(overall) | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| GRI-0803 | —(overall) | Small molecule | Type 2 NKT cells (activator) | not yet graded | No reviewed efficacy summary in this indication | |
| AB-101 (AlloNK) | Discontinued | Cell therapy | Cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| Cadefrecitinib | Discontinued | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 60 furthest-along competitors are listed; 3 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow BZE2204 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.